Orthopedic implant major United Orthopedic Corporation (聯合骨科) detailed its operational outlook at the Taipei Exchange (TPEx) performance presentation themed "Smart Medical and Edge AI" on May 20, 2026. General Manager Lin De-chien indicated that while Q1 net profit faced a sharp decline due to foreign exchange headwinds and front-loaded capacity expenditures, full-year 2026 consolidated revenue remains firmly on track for double-digit year-over-year growth.

Headwinds and Cost Structures

Lin explained that the Q1 net income contraction stemmed primarily from unfavorable foreign exchange variances and strategic headcount expansions across R&D, international clinical sales, and production lines. These human capital investments are expected to normalize by Q2 2026 and serve as the infrastructure supporting the company's upcoming revenue scaling.

Regarding international trade adjustments, Lin clarified that the tariffs paid under the US International Emergency Economic Powers Act (IEEPA), which spanned from April 2025 to February 2026, are currently undergoing an official tax refund application process. Furthermore, since February 24, 2026, the updated US import tariff has settled at a flat 10%, which exerts a minimal, well-buffered impact on United's localized gross margins in the Americas market.

Digital Orthopedics and Product Pipelines

United’s technology-assisted surgical pipelines—including navigation systems, orthopedic surgical robotics, and 3D-printed patient-specific implants—are demonstrating rising clinical penetration rates across major hospitals.

On the regulatory and product development front, United expects to secure US FDA clearances for two major systems by the end of 2026:

1. U-Motion Acetabular System: A modular acetabular cup solution engineered for high flexibility to accommodate diverse anatomical and clinical variables in total hip arthroplasty (THA).
2. United Reconstruction Tapered Wedge System: Designed for revision surgeries presenting complex bone defects. The implant utilizes 3D-printed trabecular bone structures to mimic cancellous architecture, optimizing biological fixation and osseointegration efficiency.

Note: These two high-margin pipelines are projected to begin active financial contributions to United’s top-line scaling starting in early 2027.

Resource: 聯合骨科2026年拚績增兩位數